Recombinant relaxin-2
Serelaxin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Serelaxin →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
Recombinant growth-factor-related cosmetic ingredient
sh-Oligopeptide-1
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for sh-Oligopeptide-1 →Research reference
ShK toxin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for ShK toxin →Endogenous peptide
Spexin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Spexin →- Emerging
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 4Open signals 1- Publication state
- Published profile
- Verified source records
- Evidence record in preparation
- Chemistry record
- No governed record published
- Regulatory entries
- No published regulatory entry on file
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Growth hormone secretagogue peptide
Tabimorelin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Tabimorelin →Antimicrobial peptide
Tachyplesin I
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Tachyplesin I →TRH-related peptide analog
Taltirelin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Taltirelin →GLP-1 receptor agonist peptide
Taspoglutide
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Taspoglutide →- Developing
Synthetic thymosin-related research peptide
TB-500
TB-500 is a non-standardized market name commonly associated with a synthetic fragment or derivative of thymosin beta-4. Thymosin beta-4 binds actin and has been studied in cell migration, angiogenesis, inflammation, and repair; those findings cannot automatically be attributed to every product sold as TB-500.
Evidence and record details
Evidence integrity map
Human 3Preclinical 17Durable IDs 28Open signals 3- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- 25 open research questions
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
- Emerging
Teduglutide is a GLP-2 analog studied in short bowel syndrome and intestinal failure. The clinical question concerns outcomes such as parenteral support and patient experience in defined populations.
Evidence and record details
Evidence integrity map
Human 0Preclinical 0Durable IDs 5Open signals 1- Publication state
- Published profile
- Verified source records
- 185 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Glycopeptide antibiotic
Teicoplanin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Teicoplanin →Lipoglycopeptide antibiotic
Telavancin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Telavancin →Research reference
Temporin A
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Temporin A →Antimicrobial peptide
Temporin L
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Temporin L →- Developing
Teriparatide is the recombinant 1–34 amino-acid fragment of human parathyroid hormone and retains the receptor-active N-terminal region of PTH. Intermittent subcutaneous exposure activates PTH1 receptors in bone and kidney; in bone it increases osteoblast activity and remodeling, producing an anabolic treatment effect when used according to an approved regimen. Its effects depend on exposure pattern: intermittent therapeutic administration is not equivalent to sustained endogenous parathyroid-hormone excess. Evidence and authorization are formulation-, indication-, population-, duration-, and sequence-specific.
Evidence and record details
Evidence integrity map
Human 1Preclinical 1Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
- Developing
Tesamorelin is a stabilized N-terminally modified analog of the 44-amino-acid human growth hormone–releasing hormone. It activates pituitary GHRH receptors, increasing endogenous growth-hormone release and downstream IGF-1 signaling. In the labeled population this pathway reduces visceral adipose tissue; it is not a general weight-loss mechanism.
Evidence and record details
Evidence integrity map
Human 16Preclinical 0Durable IDs 28Open signals 3- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 1 published regulatory entry
- Research questions
- 24 open research questions
- Evidence review date
- Documented human review recorded Sep 8, 2026
Source verification checks records; it does not itself approve scientific conclusions.
Synthetic peptide
Testagen
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Testagen →
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.